Fig 1: The biomarker of therapeutic efficacy in pre-treatment tumor samples.a RNA-seq and IHC for baseline and post-treatment samples. b CISH was highly expressed in baseline tumor samples in RNA-seq expression from tumor responders (n = 7) compared with non-responders (n = 7). c CISH RNA-seq expression in baseline samples could predict TKI efficiency (n = 14). d The difference in OS between high (n = 6) and low (n = 8) CISH RNA-seq expression. e The difference in EFS between high (n = 4) and low (n = 10) CISH RNA-seq expression. f CISH was highly expressed in baseline tumor samples in IHC expression from tumor responders (n = 6) compared with non-responders (n = 6). g CISH IHC expression in baseline samples could predict TKI efficiency (n = 12). h The difference in OS between high (n = 6) and low (n = 6) CISH IHC expression. i The difference in EFS between high (n = 6) and low (n = 6) CISH IHC expression. Representative IHC images (5X and 40X) for CISH in responder (j) and non-responder (k) tumors. Scare bar, 400µm for 5X images and 40µm for 40X images. Significant enrichment for TCR signaling pathway (l) and T cell mediated cytotoxicity pathway (m) in high CISH RNA-seq expression group (n = 7). CISH expression was associated with Afatinib efficacy in DepMap LUAD cell-lines with EGFR mutations in (n) PRISM secondary screen (n = 8) and (o) CTRP database (n = 12), the regression line is blue, and the shading indicates the 95% CI. p The difference in OS between high and low CISH expression in TCGA-LUAD with EGFR mutations (p = 0.00022) (n = 59). q The difference in PFS between high and low CISH expression in TCGA-LUAD with EGFR mutations (p = 0.00078) (n = 50). Centers, boxes, whiskers, and dots indicate medians, quantiles, minima/maxima, and outliers, respectively in (b) and (f). Two-sided Wilcoxon rank sum test was used for comparison in b and f. Statistical comparisons in d, e, h, i, p and q were used by log-rank test. Source data are provided as a Source Data file. PR: partial response; SD: stable disease; PD: progressive disease; AUC: area under curve; IHC: immunohistochemistry; IC50: half maximal inhibitory concentration; TCR: T-cell receptor; CISH: Cytokine-Inducible SH2-Containing Protein.
Supplier Page from Abcam for Anti-CISH/CIS antibody - C-terminal